| URL | http://www.biopharma-reporter.com/Markets-Regulati |
| Source | Biopharma Reporter |
| Date Published | 02/03/2017 |
| Author Name | Dan Stanton |
| Company/Division name | Amgen |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Total number of jobs (added or to be added): | 1600 |
| Year reshoring announced: | 2017 |
| Domestically, the work will be done: | In-house |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Biotechnology Products |
| What domestic positive factors made reshoring more attractive? | , Trump |